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Due to its high sensitivity, compact size and low cost Ion Mobility Spectrometry (IMS) has the 
potential to become a point-of-care breath analyzer. Therefore, we developed a prototype of a 
compact, closed gas loop IMS with gas chromatographic (GC) pre-separation and high resolving 
power of R = 90. In this study, we evaluated the performance of this GC-IMS under clinical conditions 
in a COPD study to find correlations between VOCs (10 ppbv to 1 ppmv) and COPD. Furthermore, in 
order to investigate possible correlations between ultra-low concentrated breath VOCs (0.1 pptv to 
1 ppbv) and COPD, a modified mass spectrometer (MS) with atmospheric pressure chemical ionization 
(APCI) and GC pre-separation (GC-APCI-MS) was used. The GC-IMS has been used in 58 subjects 
(21 smokers with moderate COPD, 12 ex-smokers with COPD, 16 healthy smokers and 9 non-
smokers). GC-APCI-MS data were available for 94 subjects (21 smokers with moderate COPD, 25 ex-
smokers with COPD, 25 healthy smokers and 23 non-smokers). For 44 subjects, a comparison 
between GC-IMS and GC-APCI-MS data could be performed. Due to service intervals, subject 
availability and corrupt data, patient numbers were different for GC-APCI-MS and GC-IMS 
measurements. Using GC-IMS, three VOCs have been found showing a significant difference between 
healthy controls and patients with COPD. In the GC-APCI-MS data, we only observed one distinctive 
VOC, which has been identified as 2-pentanone. This proof-of-principle study shows the potential of 
our high-resolution GC-IMS in the clinical environment. Due to different linear dynamic response 
ranges, the data of GC-IMS and GC-APCI-MS were only comparable to a limited extent.  
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1. Introduction 
The analysis of volatile organic compounds (VOCs) in exhaled breath has great potential to non-
invasively diagnose and monitor respiratory and systemic diseases. Many different technologies are 
available and currently used to analyze breath VOCs, such as sensor based electronic noses [1, 2], gas 
chromatography – electron ionization - mass spectrometry (GC-EI-MS) [3, 4], selected ion flow tube-
mass spectrometry (SIFT-MS) [5], proton transfer reaction mass spectrometry (PTR-MS) [6, 7] or ion 
mobility spectrometry (IMS) with gas chromatographic pre-separation by a multi-capillary column 
(MCC) [8, 9]. 
At present, the results of the different methods are hard to compare, but most of them have been able 
to show differences between COPD patients and controls or other diseases like asthma or cancer [10–
15]. For example, it is already shown [14], that the BioScout MCC-IMS (B&S Analytik, Dortmund, 
Germany)  provides sufficient sensitivity to detect specific COPD related VOCs. However, in order to 
reach this sensitivity, a high sample volume in the range of 10-50 mL is necessary, which can be 
achieved by MCC with comparatively high flow rate and high sample capacity [16]. Nonetheless, the 
MCC separation power is limited, which might lead to chemical cross sensitivities in the IMS due to 
co-eluting compounds. Moreover, because of the low mobility resolving power of the IMS [17], two 
or more analytes with similar drift times might not be separated. Furthermore, the systems need 
continuous flow of dry and clean drift gas provided by a gas cylinder or laboratory gas supply. 
Since IMS has the potential to be further developed towards point-of-care applications, we developed 
a prototype of a compact, closed gas-loop GC-IMS [18]. Compared to the IMS used in the BioScout 
MCC-IMS, which has a mobility resolving power of about R = 15 (Drift time/Full Width at Half 
Maximum (FWHM)) [17], our IMS combines much higher mobility resolving power of R = 90 with 
highest sensitivity [19]. Due to its high sensitivity, only 0.2 mL of breath are required. Thus, the IMS 
can be coupled to a standard GC capillary column for pre-separation providing better separation power 
as compared to MCC. Hence, cross sensitivity is decreased. In addition, the system is equipped with a 
filter recirculation system and does not need any external gas supply. Since this prototype has not been 
used in a clinical study yet, our objective is to evaluate this system in a clinical COPD study.  
Another focus of our work is to investigate possible correlations between ultra-low concentrated 
breath VOCs (0.1 pptv to 1 ppbv) and COPD by using a modified ultra-high sensitive mass 
spectrometer with atmospheric pressure chemical ionization and GC pre-separation (GC-APCI-MS) 
[20, 21]. It is reported [22] that for trace components, the ionization efficiency of APCI is 103-104 
times greater than that of electron “impact” ionization (EI) at reduced pressures used in standard GC- 
MS systems. Thus, another aim of this work is to gather additional information from ultra-low 
concentrated breath VOCs not detectable with standard GC- MS using practical breath sample 
volumes or GC-IMS. Furthermore, the GC-APCI-MS data are compared with GC-IMS data. Since 
both systems use the same atmospheric pressure chemical ionization, we expect some correlations 
between both data sets.   
The two different analysis technologies have been used in a large COPD study that was performed in 
two German centers for lung research (“Biomedical Research in Endstage and Obstructive Lung 
Disease Hannover (BREATH)” and “Universities Giessen and Marburg Lung Centre (UGMLC)”). 




2.1 Experimental setup 
2.1.1 GC-IMS 
For the breath measurements presented in this work, a novel, compact, closed gas loop high-resolution 
IMS was used. A detailed description of the system can be found elsewhere [18]. The two main 
components are a drift tube IMS and an isothermal GC oven with a 10 m standard capillary column 
(Restek, RTX volatiles, ID of 530 μm, film thickness of 2 μm). The GC-IMS is equipped with a filter 
recirculation system providing both a continuous supply of dry and clean drift gas and GC carrier gas, 
so that no external gas supply is needed. All relevant operating parameters are summarized in online 
supplement 1. 
The IMS with a length of 7.5 cm achieves a mobility resolving power of R = 90 (Drift time/FWHM) at 
a drift voltage of 5 kV [19]. A radioactive electron source (300 MBq 3H) is used for ionization. It 
operates in the positive mode at 40 °C and 10 mbar above ambient pressure. The drift gas flow is 
150 sccm. During operation a defined sample gas flow of 100 sccm is pumped from the sample inlet 
through a sample loop with a volume of 0.2 mL. The sample loop is injected via a 6-port-valve into 
the GC carrier gas stream. The carrier gas flow is 4 sccm for the first 20 min. After 20 min the flow 
rate is increased to 20 sccm (conditioning flow rate) for 25 min (conditioning time) in order to elute all 
remaining compounds. The GC is operated at a constant temperature of T = 50 °C. After passing the 
GC, the carrier gas flows into the IMS ionization region. Thus, all peaks found in GC-IMS 
measurements are characterized by their IMS drift time, GC retention time and peak area, which 
relates to the compound concentration. 
In order to determine the detection limit and linear dynamic response range of the GC-IMS, acetone 
has been used as a model substance for dry conditions. Of course, the results will differ for other 
compounds depending on their proton and electron affinities, and retention times. For the acetone 
dimer, a detection limit of 6.9 ppbv has been calculated. As seen in Figure 1, the linear dynamic 
response range with respect to the acetone dimer spans from 10 ppbv to 1 ppmv. Since ionization is 
based on APCI, the acetone intensity is strongly moisture-dependent. However, in [24] it is shown, 
that the chosen GC parameter allow an adequate separation of water and acetone. Thus, the moisture 
effect can be neglected in our GC-IMS for acetone and for all compounds with even longer retention 
times. 
 
Figure 1: Calibration curve of acetone measured by GC-IMS. 
2.2.2 GC-APCI-MS 
In addition to the GC-IMS, a GC-APCI-MS was used [20, 21]. Loaded Tenax TA adsorption tubes 
were therefore heated up to 180 °C for 5 min in a thermal desorption system (Gerstel TDS 3). A 
constant flow of 23 sccm nitrogen was used to flush the tubes. 4 sccm of it were directed through a 
cryo trap which was cooled by liquid nitrogen to -10°C. A Tenax TA liner was used for trapping. After 
8.5 min the cold injection system (Gerstel CIS 4) was heated up to 200 °C with a rate of 12 K/s and 
the desorbed gas was injected into the GC (Agilent 7890) at a flow rate of 3 sccm. The initial GC 
temperature was 30 °C. It was increased to 220 °C after 10 min. of acquisition. The GC column was a 
30 meter RTX-Volatiles (Restek) with an inner diameter of 530 μm and a film thickness of 2 μm. The 
GC gas flow was further diluted with approx. 600 sccm of dry air and then ionized in our atmospheric 
pressure chemical ionization (APCI) source using a radioactive 300 MBq 3H source identical to the 
source used in our IMS. The ionized sample gas was then transferred via gas flow and electric fields 
into a time-of-flight mass spectrometer (Bruker micrOTOF II). All relevant parameters are 
summarized in online supplement 2. 
Since different detection limits and in particular different linear dynamic response ranges of both 
systems (GC-IMS and GC-APCI-MS) affect the interpretation of our experimental results, below these 
parameters are also provided for the GC-APCI-MS. However, for better understanding of our 
experimental results, the different analytical methods should be compared not only by the detection 
limits of the analyzers, but by including sample pre-concentration, thermal desorption effects and pre-
separation resolving power. 
The detection limit and the linear dynamic response range of the GC-APCI-MS were determined 
based on acetone as model substance. Again, the results will differ for other compounds depending on 
their proton and electron affinities, retention times and adsorption characteristic. Due to the soft and 
more efficient ionization process at atmospheric pressure for most substances and the significant lower 
noise of the MS detector (Micro-channel plate) in comparison to the IMS detector (Faraday plate), 
ultra-low detection limits in the ppqv-range can be obtained with APCI-MS using a direct sample inlet. 
For example, the detection limit of acetone in clean dry air is about 600 ppqv for APCI-MS [25].  
However, in this study, the APCI-MS is coupled to a thermal desorption system (TDS) and a gas 
chromatograph (GC) for pre-separation. Thus, pre-concentration using adsorption tubes and resolving 
power of the GC depending on column length, column flow, column temperature etc. influence the 
detection limits in this setup (GC-APCI-MS). In this case, a detection limit of 400 ppqv was 
determined for acetone with respect to the whole measurement process. The resulting calibration curve 
is given in Figure 2. Due to a significant higher sample volume concentrated on the Tenax TA tubes 
compared to the sample volume used in the GC-IMS, the linear dynamic response range shifts towards 
lower concentrations. The linear response for acetone just reaches up to 5 ppbv for the GC-APCI-MS, 
which is below the detection limit of the GC-IMS. Thus, for the breath measurements in this study, 
two systems are available differing in their linear dynamic response ranges and detection limits which 
can lead to different correlations of VOCs in breath and COPD.   
 
Figure 2: Calibration curve of acetone measured by GC-APCI-MS.  
2.2 Subjects 
The GC-IMS has been used in 58 subjects (21 smokers with moderate COPD, 12 ex-smokers with 
COPD, 16 healthy smokers and 9 non-smokers). GC-APCI-MS data are available for 94 subjects (21 
smokers with moderate COPD, 25 ex-smokers with COPD, 25 healthy smokers and 23 non-smokers). 
For 44 subjects, a comparison between GC-IMS and GC-APCI-MS data could be performed. Due to 
service intervals, subject availability and corrupt data, patient numbers are different for GC-APCI-MS 
and GC-IMS measurements. However, Table 1 shows that the demographics of subjects available for 
the analysis by GC-IMS and by GC-APCI-MS were comparable. Subjects had to be free of 
exacerbations or acute infections within four weeks prior to the study day. The study was conducted in 
accordance with Good Clinical Practice and the Declaration of Helsinki. Subjects gave their written 






Table 1: Subjects demographics. FVC: forced vital capacity, %pred=% of predicted normal, FEV1:=forced expiratory 
volume in 1 second, FeNO:=level of exhaled nitric oxide, CO:=exhaled carbon dioxide, COHb:=calculated 





Non/Ex-smoker Smoker Non/Ex-smoker Smoker 
healthy COPD healthy COPD healthy COPD healthy COPD 
n 9 12 16 21 23 25 25 21 
Gender (f/m) 5f/4m 9f/3m 7f/9m 12f/9m 14f/9m 12f/13m 15f/10m 9f/12m 
Age (y) 44 ± 16 65 ± 05 49 ± 11 62 ± 07 37 ± 14 65 ± 05 46 ± 12 62 ± 06 




































26.1 ± 4.9 26.5 ± 3.1 23.2 ± 3.6 29.4 ± 5.1 25.5 ± 
4.7 
26.8 ± 3.8 
FVC(L) 4.8 ± 1.0 1.6 ± 1.7 4.4 ± 0.8 3.1 ± 1.9 4.5 ± 1.0 2.6 ± 1.8 4.3 ± 0.7 3.1 ± 2.1 








FEV1(L) 3.7 ± 0.8 0.9 ± 1.0 3.3 ± 0.7 1.8 ± 1.2 3.6 ± 0.8 1.3 ± 1.0 3.2 ± 0.6 1.7 ± 1.2 






















75.7 ± 4.3 46.1 ± 
24.7 










10.8 (9.5) 9.5 (5.0) 15.0 (8.0) 21.5 
(16.5) 
9.0 (5.0) 10.5 (7.0) 
CO 2.0 (3.0) 2.0 (0.5) 10.0 (3.0) 10.0 
(16.0) 




COHb 0.9 (1.1) 0.9 (0.3) 2.2 (0.5) 2.2 (2.6) 0.9 (0.4) 0.9 (0.4) 2.2 (0.8) 2.2 (2.1) 
 
2.3 Study design and collection of breath samples 
The study was from December 2013 to August 2015. Subjects visited the site on a single day. After 
undergoing thorough physical examination and providing informed consent, subjects were asked to 
give breath samples. At first, exhaled carbon monoxide (Smokelyzer, Bedfont, Kent, UK) was 
analyzed to verify the smoking status. Then, for the collection of breath samples for GC-IMS analysis 
subjects inhaled through an A2 carbon filter and exhaled into a stainless steel tube sampling reservoir 
(50 cm length, 4 cm inner diameter) under exhalation flow control (3 min pre-sampling/5 min 
sampling time) . For the GC-IMS measurements, the exhaled breath was continuously pumped with 
100 sccm from the reservoir through the sample loop of the GC-IMS. The content of the sample loop 
was injected into the GC carrier gas. 
Immediately afterwards, subjects were asked to exhale into a setup using a CO2 triggered (4%) pump 
to sample alveolar breath. The subjects used the same mouth piece with A2 filter inhalation. After at 
least three inhalation/exhalation cycles to remove accumulated environmental VOCs from the lung, 50 
mL of breath were continuously drawn onto a Tenax TA tube. 
2.4 Identification of VOCs using reference substances 
A subset of 19 compounds was chosen for external standard validation and identification. The 
reference compounds chosen for external standard measurements included alcohols, aldehydes, 
ketones and aromatic compounds. Defined test gas concentrations in the ppbv range were generated via 
permeation tubes and subsequent gas dilution. These test gases were analyzed using both GC-IMS and 
GC-APCI-MS, in order to determine GC-IMS retention times, IMS drift times and GC-APCI-MS 
retention times, see Table 2. To compare the results with other IMS devices, the reduced mobilities 
were calculated. However, it has to be noted, that several parameters besides temperature and pressure 
affect the ion mobility. Thus, reduced ion mobilities of different IMS devices do not necessarily 
match. 
Table 2: List of reference compounds analyzed by GC-IMS and GC-APCI-MS. 





retention time in s 
Ethanol 64-17-5 40 1.90 402 
2-Propanol 67-63-0 43 1.80 515 
Isoprene 78-79-5 44 1.83 525 
Acetone 67-64-1 46 1.74 541 
Acetonitrile 75-05-8 48 1.92 581 
2,3-Butanedione 431-03-8 63 1.67 881 
Butanal 123-72-8 66 1.67 + 1.51 889 
2-Butanone 78-93-3 69 1.86 909 
1-Butanol 71-36-3 106 1.65 1103 
2-Pentanone 107-87-9 116 1.74 1207 
Pentanal 110-62-3 127 1.59 + 1.35 1241 
1-Pentanol 71-41-0 211 1.54 1434 
Toluol 108-88-3 223 1.91 + 1.73 1455 
2-Hexanone 591-78-6 266 1.63 1531 
Hexanal 66-25-1 278 1.50 1568 
1-Hexanol 111-27-3 478 1.45 1795 
3-Heptanone 106-35-4 556 1.56 + 1.21 1919 
2-Heptanone 110-43-0 570 1.52 + 1.17 1948 
Cyclohexanone 108-94-1 701 1.67 + 1.32 2111 
 
2.5. Data analysis  
2.5.1 GC-IMS data 
In order to find biomarkers discriminating COPD patients from healthy controls, the GC-IMS samples 
were investigating by univariate analysis. In the first step, data from GC-IMS were pre-processed, 
such as each dataset of a breath sample is represented by a matrix of signal intensities where the x-axis 
indicates the IMS drift time in milliseconds, the y-axis indicates the GC retention time in seconds and 
the matrix values indicate signal intensities in volts. In Figure 3, an exemplary excerpt from the GC-
IMS data of a COPD smoker is shown.  
 
Figure 3: Excerpt from the GC-IMS data of a COPD smoker. 
Due to variations in atmospheric pressure, both IMS drift time as well as GC retention time changed 
slightly from day to day. Since both the IMS and the GC temperature are controlled and the moisture 
content of the IMS drift gas and GC carrier gas is constant over months, the influence of these 
parameters on drift and retention time is negligible. Furthermore, the IMS pressure was automatically 
logged in every measurement for IMS drift time corrections. The retention time was corrected by 
linear alignment based on peaks that appear in every breath measurement, e.g. Acetone.  
In the second step of the univariate analysis, peaks were determined using a peak finder algorithm 
written in MATLAB. A signal was classified as a peak, when the intensity of the signal was 10 times 
higher than the standard deviation of the noise. In order to exclude outliers, only peaks appearing in at 
least one group (COPD smokers, COPD ex-smokers, healthy smokers and healthy non-smokers) in at 
least 50 percent of all measurements were considered. In the last step, a statistical analysis is 
conducted based on 45 GC-IMS peaks (classified as explained above) applying Welch’s t-test. 
2.5.2 GC-APCI-MS data 
The GC-APCI-MS data were analyzed as described in 2.5.1. The dataset of one breath sample is 
represented by a matrix of signal intensities where the x-axis indicates the mass-to-charge ratio in m/z, 
the y-axis indicates the GC retention time in seconds and the matrix values indicate signal intensities 
in counts. Figure 4 shows an excerpt from the GC-APCI-MS data of the COPD smoker. Due to 
different GC parameters (e.g. flow rate, temperature, length) the retention time span of 0 - 25 min of 
the GC-APCI-MS fits to the retention time span of 0 - 300 s of the GC-IMS. 
 
Figure 4: GC-APCI-MS data of a COPD smoker. 
Comparing Figure 3 and Figure 4, it can be seen, that the GC-APCI-MS data includes considerably 
more peaks. This is due to the 250-fold higher sample volume of 50 mL that was collected onto the 
Tenax TA tube. The univariate analysis of the GC-APCI-MS data was performed as described above. 
In total 102 peaks (classified as explained above) were analyzed using Welch’s t-test. 
2.6 Statistical analysis 
Welch’s t-test was applied to compare the four groups (COPD smokers, COPD ex-smokers, healthy 
smokers and healthy non-smokers) with respect to all peaks detected. Welch's t-test is an adaptation of 
Student's t-test and is more reliable in case of unequal variances and unequal sample sizes. For all 
tests, a 2-sided significance level of 1% was applied, unless otherwise noted. Due to the exploratory 
nature of this study, no further adjustment for multiple testing was done. The data of breath VOCs are 
displayed as median, interquartile range (IQR) and whisker with a maximum length of the 1.5-fold 
IQR range for every group in the respective figures. 
3. Results 
3.1 GC-IMS 
45 GC-IMS VOC peaks were included into the statistical analysis. In Table 3, the 20 most abundant 
compounds with respect to the mean intensity per subject are shown. Two or more peaks having the 
same retention time are associated to one compound, since the peaks are assumed to be monomer and 












p-value < 0.01 
Smoker vs. 
non-smoker  
p-value < 0.01 
COPD vs. 
healthy  
1 35 1.64   
Ethanol 40 1.90 X  
2-Propanol 43 1.80   
4 43.5 1.67   
Acetone 46 1.74   
6 48 1.88 X  
Acetonitrile 48.5 1.92 X  
8 49 1.80   
9 54.5 1.65   
10 57 1.77 + 1.69 X  
11 58 1.88   
2-Butanone 69 1.86 X  
13 101 1.78   
1-Butanol 106 1.65   
15 108 1.87   
2-Pentanone 116 1.74   
17 127 1.80 + 1.67   
18 142 1.85 X  
19 169 1.76 + 1.54  X 
20 219.5 1.80 + 1.49  X 
 
In active smokers, we found significantly (p < 0.01) higher levels for six VOCs (ethanol, VOC 6, 
acetonitrile, VOC 10, 2-butanone, VOC 18) compared to ex- and non-smokers. Acetonitrile and 2-
butanone are known as smoking related compounds [26]. The data for acetonitrile and 2-butanone are 
displayed in Figure 5a and 5b. The six compounds also correlate well with the level of exhaled carbon 
monoxide considering all groups as well as smokers only.  
Being aware that active smoking has a pronounced effect on the VOC composition of exhaled breath, 
we analyzed the data separately for smokers and non/ex-smokers with respect to COPD markers. We 
found three VOCs that significantly differed between healthy subjects and COPD patients in the group 
of non/ex-smokers (p < 0.01, n = 9 vs.12). These three VOCs could be also found in the group of 
smokers to be significantly different (p < 0.01, n = 16 vs. 21) additionally to four further VOCs. Thus, 
three of the 45 VOCs that were included into the analysis show a significant difference between 
healthy controls and patients with COPD both in the group of smokers and in the group of non/ex-
smokers. Two of these three VOCs rank among the 20 most abundant peaks. The two VOCs are given 
in Table 3 as “Compound 19 and 20” and are displayed in Figure 5c and 5d. However, the two 
compounds are not identified, yet. The third compound has low intensity near the chosen S/N 
threshold ratio of 10 and is not identified, too. 
 
Figure 5: Box-and-whisker plots of four compounds. In a) and b) acetonitrile as well as 2-butanone is shown, clearly 
distinguishing active smoker from ex- and non-smoker. In c) and d) two compounds are shown significantly 
discriminating between COPD patients and healthy controls. 
3.2 GC-APCI-MS 
Among the 102 VOC peaks detected by GC-APCI-MS and included into the analysis, 16 were 
significantly different (p < 0.01) between smokers and non/ex-smokers. Four of these compounds 
correlate with the level of exhaled carbon monoxide, considering all groups as well as smokers only. 
The two identified smoker related peaks in the GC-IMS data, acetonitrile and 2-butanone, also 
distinguish smokers from non/ex-smokers in the GC-APCI-MS data (p = 0.01 and p = 0.05). Since 
other VOCs are not identified yet, they cannot be compared to the GC-IMS data. 
Surprisingly, we only found one VOC that significantly differs (p < 0.01) between healthy subjects 
and COPD patients in the group of non/ex-smokers (p = 0.003, n = 23 vs.25) and in the whole group 
of subjects (p = 0.005, n = 48 vs. 46). This compound was identified as 2-pentanone. In the group of 
smokers (n = 25 vs. 21), no VOC was found to be significantly (p < 0.01) different in the groups.  
3.3 Comparison between GC-IMS and GC-APCI-MS data 
Investigating the correlation between GC-APCI-MS and GC-IMS data, it becomes obvious, that 
among the VOCs identified by reference compounds the number of close correlations is limited. For 
smoking related compounds, e.g. acetonitrile, the correlation is high (r = 0.73, p = 1E-8), but for e.g. 
ethanol or 2-pentanone it was found to be low (r < 0.5).  
For 2-pentanone the difference between controls and COPD patients was only observed in the GC-
APCI-MS data. Since 2-pentanone is one of the investigated reference compounds, the GC-IMS 
retention time as well as the IMS drift time from 2-pentanone is known. The corresponding peak in the 
GC-IMS data does not significantly distinguish COPD patients from healthy controls. As 2-pentanone 
is the only COPD related compound found in the GC-APCI-MS data, the two compounds significantly 
discriminating between COPD patients and healthy controls in the GC-IMS data could not be 
identified as significant from the GC-APCI-MS data. 
4. Discussion 
This proof-of-principle study shows the potential of our closed gas loop, high resolution GC-IMS in 
clinical studies. The smoking related differences and correlations indicate that the GC-IMS data are 
valid. Thus, the GC-IMS provides potentially valuable diagnostic information based on VOC 
biomarker in exhaled breath for non-invasive diagnostics. In this study, three VOCs have been found 
with GC-IMS that significantly differentiate between healthy subjects and COPD patients. 
The results show that the improved analytical performance of our GC-IMS is sufficient to analyze 
complex breath samples. The chosen standard GC-column is especially suitable for the separation of 
volatile organic compounds. In combination with the high-resolution ion mobility spectrometer high 
separation power is achieved. Furthermore, the system is very sensitive. Detection limits in the single-
digit ppbv range can be reached. Almost 50 clearly separated peaks were detected in a GC-IMS breath 
spectrum using ultra-low sample volume of just 0.2 mL. Thus, our GC-IMS provides sufficient 
analytical power for direct analysis of breath samples without any pre-concentration. The advantage of 
a direct analysis is that the measurement is not affected by any sample collection procedure, e.g. 
“selective” breath sampling on Tenax TA. Moreover, considering the instrumentation effort and 
relatively low cost, GC-IMS has large potential for real-time and bed-site analysis. 
However, while this feasibility study clearly demonstrates the utility of GC-IMS for exhaled breath 
VOC analysis to discriminate COPD patients from healthy controls, some limitations of the current 
experimental design and analysis were recognized. For real-time online analysis, it would be desirable 
to reduce the current measurement time to less than 20 minutes. This time has been chosen to ensure 
that most breath VOCs have eluted from the GC column. Considering the GC-IMS breath 
measurements in this study, it is noteworthy that the majority of the VOCs have eluted after a few 
minutes. Hence, when using the GC-IMS in further studies, the GC parameters should be optimized 
with respect to separation power and measuring time. Therefore, it is possible to use a flow scheme or 
to vary the GC temperature. In order to better assess the possible effects, further observations are 
necessary. 
Another focus of our work is to investigate possible correlations between low concentrated breath 
VOCs and COPD by using a GC-APCI-MS. Compared to our compact GC-IMS, breath measurements 
analyzed with GC-APCI-MS contained significantly more peaks due to the 250-fold higher sample 
volume and the lower detection limits. Thus, by using the GC-APCI-MS mainly low concentrated 
breath VOCs are analyzed. Comparable to the GC-IMS data, several smoking related peaks have been 
found in the GC-APCI-MS data, but only a small fraction of these peaks correlate with the CO level. 
This result could be attributed to two issues. First, the linear dynamic response range of the GC-APCI-
MS system just reaches up to 5 ppbv. Since the majority of smoking related compounds in breath have 
higher concentrations, the GC-APCI-MS operates close to the saturation level. Thus, for higher 
concentrations the detector intensity becomes independent of the concentration, e.g. doubling the 
compound concentration does not lead to higher peak intensity. However, doubling the compound 
concentration possibly leads to doubling the measured CO level. Thus, no correlation can be detected. 
Second, due to the ultra-high sensitivity of the GC-APCI-MS system, it is possible that we detected 
VOCs which are no direct combustion products of smoking but instead VOCs which occur due to 
metabolic changes caused by smoking. 
Furthermore, in the GC-APCI-MS data, we only found one VOC (2-pentanone) significantly 
discriminating COPD patients from healthy controls. This compound has not been found by GC-IMS. 
In contrast, with the GC-IMS three other VOCs are found differentiating COPD patients from healthy 
controls. Overall, there is just a limited number of VOCs showing close correlation between GC-IMS 
and GC-APCI-MS. Being aware that both measurement systems differ with respect to the linear 
dynamic response range, these results are not surprising. In breath, the concentration of compounds 
which can be detected by GC-IMS need to be significantly higher as for GC-APCI-MS. We assume 
that the GC-APCI-MS is in saturation for these compounds, especially when considering the pre-
concentration effect. Thus, no COPD discrimination can be seen in the GC-APCI-MS data for the 
compounds found with GC-IMS. On the other hand, the concentration of 2-pentanone in breath is 
comparatively low, which leads to a low signal intensity in the GC-IMS close to the noise level. 
Hence, it is hard to detect differences for those substances by the GC-IMS. 
Apart from this, there are other reasons which also might influence the comparability of GC-IMS and 
GC-APCI-MS data. For example, different sample collection methods were used. For GC-IMS 
measurements, exhaled breath was directly analyzed. For GC-APCI-MS measurements, just end-
expiratory breath was sampled on Tenax TA. Tenax TA is known to be a “selective” medium for high 
volatile compounds, plus, there are decomposition products interfering the discrimination from 
endogenous breath compounds [27]. Furthermore, alveolar air shows higher concentrations of 
systemic and lower concentration of exogenous substances [28]. However, this should have only a 
minor influence on the results. 
In summary, among the low concentrated breath VOCs (0.1 pptv to 1 ppbv), which can be measured by 
the GC-APCI-MS, only 2-pentanone significantly discriminates COPD patients from healthy controls. 
Thus, in this study, the investigation of low concentrated breath VOCs has not provided any new 
biomarkers discriminating COPD from healthy subjects. Most COPD related VOCs seem to appear in 
higher concentration ranges.  
5. Conclusion 
In this study, a novel, compact, closed gas loop, high-resolution GC-IMS and a modified ultra-
sensitive GC-APCI-MS were used to find COPD related biomarkers. The smoking related differences 
and correlations indicate that the GC-IMS data are valid. In this study, three VOCs differentiating 
significantly between healthy subjects and COPD patients have been found using GC-IMS. The 
identification of three COPD related GC-IMS signals support the use of the GC-IMS in larger COPD 
trials. In order to investigate possible correlations between ultra-low concentrated breath VOCs 
(0.1 pptv to 1 ppbv) and COPD, a GC-APCI-MS system has been used. Due to different linear dynamic 
response ranges, the data of GC-IMS and GC-APCI-MS are only comparable to a limited extent. 
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